Search Results - william+figg

5 Results

Sort By:

Cancer Therapeutic Based on Hypoxia Inducible Factor 1 (HIF-1) Inhibitors

Abstract: Hypoxia is a characteristic of many solid tumors resulting from accelerated cellular proliferation and inadequate vascularization. HIF-1 is a transcription factor critical for maintaining cellular homeostasis in, and adaptively responding to, low oxygen environments. HIF-1 becomes activated through binding to the transcriptional co-activator...

Published: 4/8/2024 | Inventor(s): Kirk Gustafson, Martin Schnermann, Susanna Chan, Paresma Patel, William Figg, James McMahon

Keywords(s): CANCER, Hypoxia Inhibitor, Malaria, small molecule

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics

Natural product-based anti-cancer agents: aza-Englerin analogues

Abstract: Chemotherapy resistance in a wide array of cancers is often associated with enhanced glucose uptake and dysregulation of the insulin signaling pathway. Therapeutics capable of inhibiting insulin signaling would be valuable as a stand-alone treatment and for sensitizing resistant tumors to standard chemotherapy regiments. Researchers at NCI’s...

Published: 7/3/2024 | Inventor(s): Willaim Chain, John Beutler, William Figg, Joe Ramos, Florian Suizmaier, Zhenwu Li, Daniel Fash, Ian Talisman, Cody Peer

Keywords(s): Ewing, Glycolytic, insulin, Resistance, Sarcoma

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology

SLCO1B3 Genotyping to Predict a Survival Prognosis of Prostate Cancer

Abstract: Steroid hormones have been implicated to play a fundamental role in the pathogenesis of prostate cancer. Polymorphisms in the genes that code for enzymes, or hormones involved in androgen regulatory pathway, reportedly influence risk for developing prostate cancer. Since many membrane transporters are modulators of steroid hormones absorption...

Published: 4/8/2024 | Inventor(s): William Figg, Alex Sparreboom, Douglas Price, Akinobu Hamada

Keywords(s): Androgen-directed Therapy, Biomarkers, diagnostic, Figg, genetic markers, Genomics, Hormone-Refractory, personalized medicine, predictive markers, prognostic, PROSTATE, SLCO1B3

Category(s): TherapeuticArea > Endocrinology, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Diagnostics, TherapeuticArea > Oncology

Aryl Hydantoin Heterocycle Compounds that Target the Androgen Receptor for Prostate Cancer Treatment

Abstract: Prostate cancer is the most prevalent form of cancer among all men in the United States (US). It is also the second leading cause of cancer-related deaths in the US among men, largely due to the progressively treatment resistant nature of the disease. Treatment options for early stage prostate cancer include watchful waiting, radical prostatectomy,...

Published: 4/8/2024 | Inventor(s): Berkley Gryder, Adegboyega Oyelere, Eric Raftery, Subhasish Tapadar, Nicholas Aboreden, William Figg

Keywords(s): Androgen Deficiency Disorders, Androgen dysfunctional Disorders, Androgen Receptor, Androgen Receptor Inverse Agonists, Anti-androgens, AR, ARIA, BREAST CANCER, Georgia Institute of Technology, GIT, Gryder, Hyperandrogenism, PROSTATE CANCER

Category(s): Application > Therapeutics, TherapeuticArea > Endocrinology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology

Thalidomide Analogs that Inhibit Inflammation and Angiogenesis

Abstract: Thalidomide and its close analogs (lenalidomide and pomalidomide) are widely used to treat a variety of diseases, such as multiple myeloma and other cancers as well as the symptoms of several inflammatory disorders. However, thalidomide is known for its teratogenic adverse effects when first clinically introduced in the 1950s, and is associated...

Published: 4/8/2024 | Inventor(s): Nigel Greig, Weiming Luo, David Tweedie, Nell Vargesson, Shaunna Beedle, William Figg

Keywords(s): anti-angiogenesis, ANTI-INFLAMMATORY, Lenalidomide, Pomalidomide, THALIDOMIDE

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics